Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: New melanin concentrating hormone antagonists

Journal of Medicinal Chemistry

Volumn 52, Issue 7, 2009, Pages 2076-2089

  Oyarzabal, Julen ^a,b   Howe, Trevor ^c   Alcazar, Jesús ^c   Andrés, Jose Ignacio ^c   Alvarez, Rosa M ^b   Dautzenberg, Frank ^c   Iturrino, Laura ^c   Martínez, Sonia ^b   Van Der Linden, Ilse ^c  

^a Johnson and Johnson Pharmaceutical R and D   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c NONE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 METHOXY 4 (2 PYRROLIDIN 1 YLETHOXY)PHENYL] 3 (3 PHENYLPROPYL) 1H PYRAZIN 2 ONE; 1 [3 METHOXY 4 (2 PYRROLIDIN 1 YLETHOXY)PHENYL] 3 PHENETHYLAMINO 1H PYRAZIN 2 ONE; 1 [3 METHOXY 4 (2 PYRROLIDIN 1 YLETHOXY)PHENYL] 3 PHENETHYLOXY 1H PYRAZIN 2 ONE; FUNCTIONAL GROUP; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; DATA BASE; PATENT;

CENTRAL NERVOUS SYSTEM AGENTS; DATABASES, FACTUAL; DRUG DISCOVERY; HYPOTHALAMIC HORMONES; MELANINS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PITUITARY HORMONES; PYRAZINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, PITUITARY HORMONE; SOLVENTS; STATIC ELECTRICITY; STEREOISOMERISM; WATER;

EID: 64549145417     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8016199     Document Type: Article

References (76)

1. Brown, N.; Jacoby, E. On scaffolds and hopping in medicinal chemistry. Mini Rev. Med. Chem. 2006, 6, 1217-1229.
2. Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G. "Scaffold- hopping" by topological pharmacophore search: a contribution to virtual screening. Angew. Chem., Int. Ed. 1999, 38, 2894-2896.
3. (a) Bohl, M.; Dunbar, J.; Gifford, E. M.; Heritage, T.; Wild, D. J.; Willett, P.; Wilton, D. J. Scaffold searching: automated identification of similar ring systems for the design of combinatorial libraries. Quant. Struct.-Act. Relat. 2002, 21, 590-597.
4. (b) Lauri, G.; Bartlett, P. A. CAVEAT: a program to facilitate the design of organic molecules. J. Comput.-Aided Mol. Des. 1994, 8, 51-66.
5. (4) Bergmann, R.; Linusson, A.; Zamora, I. SHOP: Scaffold HOPping by GRID-based similarity searches. J. Med. Chem. 2007, 50, 2708- 2717.
6. (5) Jenkins, J. L.; Glick, M.; Davies, J. W. A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes. J. Med. Chem. 2004, 47, 6144-6159.
7. Zhang, Q.; Muegge, I. Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring. J. Med. Chem. 2006, 49, 1536-1548.
8. Schneider, G.; Schneider, P.; Renner, S. Scaffold-hopping: how far can you jump? QSAR Comb. Sci. 2006, 12, 1162-1171.
9. Scitegic. Pipeline Pilot, 9665 Chesapeake Dr., Suite 401, San Diego, CA 92123-1365; available from SciTegic Inc. at http://www.scitegic. com.
10. Chemical Computing Group Inc. Molecular Operating Environment (MOE), 1010 Sherbrooke St. W, Suite 910, Montreal, QC, Canada; available from Chemical Computing Group Inc. at http://www. chemcomp.com or http://svl.chemcomp.com.
11. (a) Lewell, X. Q.; Judd, D. B.; Watson, S. P.; Hann, M. M. RECAPsretrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci. 1998, 38, 511-522.
12. (b) Degen, J.; Wegscheid-Gerlach, C.; Zaliani, A.; Rarey, M. On the art of compiling and using "drug-like" chemical fragment spaces. ChemMedChem 2008, 3, 1503-1507.
13. Advanced Chemistry Development Inc., 110 Yonge St., 14th floor, Toronto, ON, Canada, ACD/PhysChem Batch 10.00; available from ACD Inc. at http://www.acdlabs.com.
14. Needleman, P. Method of using cyclooxygenase-2 inhibitors in the treatment and pRevention of dementia. Patent WO 9843648 A1; 26 pp.
15. Zhou, P.; Kelly, M. G. Preparation of 2-(1-phenylsulfonylindol- or -indazol-4-yloxy)ethanamines as 5-HT6 receptor ligands. Patent WO 2002 059088 A1; 58 pp.
16. Ohkawa, S.; Fujii, N.; Kato, K.; Miyamoto, M. Condensed heterocyclic compounds (benzo[b]cyclopenta[e][1,4]diazepinones and analogs), their production, and use as GnRH antagonists. Patent WO 9529900 A1; 220 pp.
17. Duggan, M. E.; Lindsley, C. W.; Wisnoski, D. D. Preparation of benzamide modulators of metabotropic glutamate receptors. PatentWO 2004087048 A2; 65 pp.
18. Bromidge, S. M.; Lovell, P. J.; Goodacre, C. Preparation of cyclic urea derivatives with 5-HT2c receptor activity. Patent WO 2003057220 A1; 36 pp.
19. Engels, M. F. M.; Gibbs, A. C.; Jaeger, E. P.; Verbinnen, D.; Lobanov, V. S.; Agrafiotis, D. K. A cluster-based strategy for assessing the overlap between large chemical libraries and its application to a recent acquisition. J. Chem. Inf. Model. 2006, 46, 2651-2660.
20. Prous Science S. A. U., Provenza 388, 08025 Barcelona, Spain; available from http://integrity.prous.com/.
21. OpenEye Scientific Software Inc., 9 Bisbee Ct., Suite D, Santa Fe, NM 87508; available from http://www.eyesopen.com.
22. Boström, J. Reproducing the conformations of protein-bound ligands: a critical evaluation of several popular conformational searching tools. J. Comput.-Aided. Mol. Des. 2001, 15, 1137-1152.
23. Kirchmair, J.; Wolber, G.; Laggner, C.; Langer, T. Comparative performance assessment of the conformational model generators omega and catalyst: a large-scale survey on the retrieval of protein-bound ligand conformations. J. Chem. Inf. Model. 2006, 46, 1848-1861.
24. Grant, J. A.; Gallardo, M. A.; Pickup, B. T. A fast method of molecular shape comparison. A simple application of Gaussian description of molecular shape. J. Comput. Chem. 1996, 17, 1653-1666.
25. Boström, J.; Greenwood, J. R.; Gottfries, J. Assessing the performance of OMEGA with respect to retrieving bioactive conformations. J. Mol. Graphics Modell. 2003, 21, 449-462.
26. (a) Nicholls, A.; MacCuish, N. E.; MacCuish, J. D. Variable selection and model validation of 2-D and 3-D molecular descriptors. J. Comput.- Aided Mol. Des. 2004, 18, 451-474.
27. (b) Nicholls, A.; Grant, A. J. Molecular shape and electrostatics in the encoding of relevant chemical information. J. Comput.-Aided Mol. Des. 2005, 19 (9-10), 661-686.
28. Jennings, A.; Tennant, M. Selection of molecules based on shape and electrostatic similarity: proof of concept of "electroforms". J. Chem. Inf. Model. 2007, 47, 1829-1838.
29. Saito, Y.; Nothacker, H.-P.; Wang, Z.; Lin, S. H. S.; Frances, L.; Civelli, O. Molecular characterization of the melanin-concentrating hormone receptor. Nature 1999, 400, 265-269.
30. Chambers, J.; Ames, R. S.; Bergsma, D.; Muir, A.; Fitzgerald, L. R.; Hervieu, G.; Dytko, G. M.; Foley, J. J.; Martins, J.; Liu, W.-S.; Park, J.; Ellis, C.; Ganguly, S.; Konchar, S.; Cluderay, J.; Leslie, R.; Wilson, S.; Sarau, H. M. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature 1999, 400, 261-265.
31. Sailer, A. W.; Sano, H.; Zeng, Z.; McDonald, T. P.; Pan, J.; Pong, S.-S.; Feighner, S. D.; Tan, C. P.; Fukami, T.; Iwaasa, H.; Hreniuk, D. L.; Morin, N. R.; Sadowski, S. J.; Ito, M.; Ito, M.; Bansal, A.; Ky, B.; Figueroa, D. J.; Jiang, Q.; Austin, C. P.; MacNeil, D. J.; Ishihara, A.; Ihara, M.; Kanatani, A.; Van der Ploeg, L. H. T.; Howard, A. D.; Liu, Q. Identification and characterization of a second melaninconcentrating hormone receptor, MCH-R2. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 7564-7569.
32. Mendez-Andino, J. L.; Wos, J. A. MCH-R1 antagonists: what is keeping most research programs away from the clinic? Drug DiscoV. Today 2007, 12, 972-978.
33. Schwartz, M. W.; Woods, S. C.; Porte, D., Jr.; Seeley, R. J.; Baskin, D. G. Central nervous system control of food intake. Nature 2000, 404, 661-671.
34. Shearman, L. P.; Camacho, R. E.; Sloan Stribling, D.; Zhou, D.; Bednarek, M. A.; Hreniuk, D. L.; Feighner, S. D.; Tan, C. P.; Howard, A. D.; Van der Ploeg, L. H. T.; MacIntyre, D. E.; Hickey, G. J.; Strack, A. M. Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats. Eur. J. Pharmacol. 2003, 475, 37-47.
35. Borowsky, B.; Durkin, M. M.; Ogozalek, K.; Marzabadi, M. R.; DeLeon, J.; Heurich, R.; Lichtblau, H.; Shaposhnik, Z.; Daniewska, I.; Blackburn, T. P.; Branchek, T. A.; Gerald, C.; Vaysse, P. J.; Forray, C. Antipressant, anxiolytic and anorectic effects of a melaninconcentrating hormone-1 receptor antagonist. Nat. Med. 2002, 8, 825- 830.
36. (a) Chaki, S.; Funakoshi, T.; Hirota-Okuno, S.; Nishiguchi, M.; Shimazaki, T.; Iijima, M.; Grottick, A. J.; Kanuma, K.; Omodera, K.; Sekiguchi, Y.; Okuyama, S.; Tran, T.-A.; Semple, G.; Thomsen, W. Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J. Pharmacol. Exp. Ther. 2005, 313, 831-839.
37. (b) Chaki, S.; Yamaguchi, J.-I.; Yamada, H.; Kanuma, K.; Sekiguchi, Y. Melaninconcentrating hormone receptor 1 antagonists for the treatment of depression and anxiety. Drug Dev. Res. 2005, 65, 278-290.
38. (a) Chen, X.; Chen, X.; Fan, P.; Jaen, J.; Li, L.; Mihalic, J. T. Patent WO 04/043958 A1.
39. (b) Andersen, D.; Storz, T.; Liu, P.; Wang, X.; Li, L.; Fan, P.; Chen, X.; Allgeier, A.; Burgos, A.; Tedrow, J.; Baum, J.; Chen, Y.; Crockett, R.; Huang, L.; Syed, R.; Larsen, R. D.; Martinelli, M. Stereoselective synthesis of a MCH-R1 antagonist. J. Org. Chem. 2007, 72, 9648-9655.
40. (a) Hertzog, D. L.; Al-Barazanji, K. A.; Bigham, E. C.; Bishop, M. J.; Britt, C. S.; Carlton, D. L.; Cooper, J. P.; Daniels, A. J.; Garrido, D. M.; Goetz, A. S.; Grizzle, M. K.; Guo, Y. C.; Handlon, A. L.; Ignar, D. M.; Morgan, R. O.; Peat, A. J.; Tavares, F. X.; Zhou, H. The discovery and optimization of pyrimidinone-containing MCHR1 antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 4723-4727.
41. (b) Hertzog, D. L.; Wittig, D. R. Biphenyl amides and isosteres as MCH R1 antagonists. Curr. Top. Med. Chem. 2007, 7, 1455-1470.
42. Rokosz, L. L. Discovery and development of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Expert Opin. Drug Discov. 2007, 2, 1301-1327.
43. Takekawa, S.; Aami, A.; Ishihara, Y.; Terauchi, J.; Kato, K.; Shimomura, Y.; Mori, M.; Murakoshi, H.; Kato, K.; Suzuki, N.; Nishimura, O.; Fujino, M. T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur.J. Pharmacol. 2002, 438, 129-135.
44. Armstrong, S. A.; Hamprecht, D. W.; Jones, M.; Witty, D. R.; Al- Baranznji, K. A.; Tadayyon, M. Lactam derivatives as antagonists for human 11CBY receptors. Patent WO03033480; 87 pp.
45. Ammenn, J.; Gillig, J. R.; Heinz, L. J.; Hipskind, P. A.; Kinnick, M. D.; Lay, Y.-S.; Morin, J. M.; Nixon, J. A.; Ott, C.; Savin, K. A.; Schotten, T.; Slieker, L. J.; Snyder, N. J.; Robertson, M. A. Multicyclic compounds for use as melatonin concentrating hormone antagonists in the treatment of obesity and diabetes. Patent WO03097047; 592 pp.
46. Lehmann-Lintz, T.; Stenkamp, D.; Lenter, M.; Wieland, H.-A.; Rudolf, K.; Müller, S. G.; Lotz, R. R. H.; Arndt, K. and Lustenberger, F. Novel carboxamide compounds having an MCH-antagonistic effect medicaments containing said compounds, and methods for the production thereof. Patent WO04024702 A1; 344 pp.
47. Moriya, M.; Sakakmoto, T.; Kishino, H.; Kanatani, A. Preparation of 2-aminobenzoimidazole derivatives as antagonists of melaninconcentrating hormone receptor. Patent WO04031177 A1; 93 pp.
48. Schwink, L.; Stengelin, S.; Gossel, M.; Boehme, T.; Hessler, G.; Rosse, G.; Walser, A. Preparation of 1,3-dihydro-1,3-diphenyl-2Himidazol- 2-ones and related compounds as MCH receptor modulators for the treatment of obesity. Patent WO04011438 A1; 113 pp.
49. Otake, N.; Haga, Y.; Naya, A.; Mizutani, S.; Kanatani, A. Preparation of pyridone and related compounds as melanin concentrating hormone receptor antagonists. Patent WO05085200 A1.
50. Goodfellow, V.; Dyck, B. P.; Zhao, L.; Tamiya, J.; Grey, J.; Wade, W.; Rowbottom, M.; Zhang, M.; Vickers, T. D. Preparation of aminopyrrolidinyl pyridines as MCH receptor antagonists. Patent WO05103039 A1; 64 pp.
51. Amegadzie, A. K.; Beck, J. P.; Gardinier, K. M.; Hembre, E. J.; Ruble, J. C.; Savin, K. A.; Wakefield, B. D. Preparation of thiazolopyridinones as MCH receptor antagonists for treating and pReventing symptoms assocd. With obesity and related diseases. Patent WO06066174 A1; 154 pp.
52. Ishihara, Y.; Suzuhi, N.; Takekawa, S. Melanin-concentrating hormone anatagonists. Patent JP2001226269 A; 88 pp.
53. Dyck, B.; Zhao, L.; Tamiya, J.; Pontillo, J.; Hudson, S.; Ching, B.; Heise, C. E.; Wen, J.; Norton, C.; Madan, A.; Schwarz, D.; Wade, W.; Goodfellow, V. S. Substituted chromones and quinolones as potent melanin-concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 4237-4242.
54. Dyck, B.; Markison, S.; Zhao, L.; Tamiya, J.; Grey, J.; Rowbottom, M. W.; Zhang, M.; Vickers, T.; Sorensen, K.; Norton, C.; Wen, J.; Heise, C. E.; Saunders, J.; Conlon, P.; Madan, A.; Schwarz, D.; Goodfellow, V. S. A thienopyridazinone-based melanin-concentrating hormone receptor 1 antagonist with potent in vivo anorectic properties. J. Med. Chem. 2006, 49, 3752-3756.
55. Meyers, K. M.; Mendez-Andino, J. L.; Colson, A.-O.; Warshakoon, N. C.; Wos, J. A.; Mitchell, M. C.; Hodge, K. M.; Howard, J. M.; Ackley, D. C.; Holbert, J. K.; Mittelstadt, S. W.; Dowty, M. E.; Obringer, C. M.; Reizes, O.; Hu, X. E. Aminoethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists-increasing selectivity over hERG. Bioorg. Med. Chem. Lett. 2007, 17, 819-822.
56. Guo, T.; Hunter, R. C.; Zhang, R.; Greenlee, W. J. Microwave assisted synthesis of isothiazolo-, thiazolo-, imidazo- and pyrimido-pyrimidinones as novel MCHR1 antagonists. Tetrahedron Lett. 2007, 48, 613- 615.
57. (a) Giordanetto, F.; Inghardt, T. Thienoheterocycles, processes for preparing them, pharmaceutical compositions containing them, and their use in the treatment of obesity, psychiatric and neurological disorders. Patent WO07011286 A1; 34 pp.
58. (b) Giordanetto, F.; Inghardt, T.; Nordberg, P. Preparation of thieno[3,2-d]pyrimidin-4(3H)- one derivatives as MCH agonists. Patent WO07011284 A1; 44 pp.
59. (c) Giordanetto, F.; Inghardt, T. Benzimidazolyl-substituted thienoheterocycles, processes for preparing them, pharmaceutical compositions containing them, and their use in the treatment of obesity, psychiatric and neurological disorders. Patent WO07011285 A1; 30 pp.
60. (a) Balavoine, F.; Nicolaie, E.; Sartori, E. Preparation of hydantoin derivatives and their use as MCHR-1 antagonists. Patent WO07012661 A1; 92 pp. Balavoine, F.; Nicolaie, E.; Sartori, E. Preparation of 5- benzylideneimidazolidine-2,4-dione derivatives and their use as MCHR-1 antagonists. Patent WO07012670 A1.
61. (c) Balavoine, F.; Malabre, P.; Alleaume, T.; Rey, A.; Cherfils, V.; Jeanneton, O.; Seigneurin-Veninb, S.; Revah, F. Design and synthesis of novel hydantoin-containing melanin-concentrating hormone receptor antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 3754-3759.
62. (a) Scheneider, J.; Hauser, R.; Andreas, J. O.; Linz, K.; Jahnel, U. Differential effects of human ether-a-go-go-related gene (hERG) blocking agents on QT duration variability in conscious dogs. Eur. J. Pharmacol. 2005, 512, 53-60.
63. (b) Shah, R. R. The significance of QT interval in drug development. Br. J. Clin. Pharmacol. 2002, 54, 188-202.
64. (c) Haverkamp, W.; Breithardt, G.; Camm, A. J.; Janse, M. J.; Rosen, M. R.; Antzelevitch, C.; Escande, D.; Franz, M.; Malik, M.; Moss, A.; Shah, R. The potential for QT prolongation and proarrhythmia by non-anti-arrhythmia drugs: clinical and regulatory implications: report on a policy conference of the European Society of Cardiology. CardioVasc. Res. 2000, 47, 219-232.
65. 2 in a cell culture incubator. After loading, 20 μL of serial dilutions of the test compound are added and cells are further incubated for 20 min at room temperature in the dark. After 20 min, 20 μL of a submaximal MCH concentration is added and changes in intracellular calcium are recorded directly in a FLIPR III apparatus (Molecular Devices).
66. Birchall, K.; Gillet, V. J.; Harper, G.; Pickett, S. D. Evolving interpretable structure-activity relationship models. 2. Using multiobjective optimization to derive multiple models. J. Chem. Inf. Model. 2008, 48, 1558-1570.
67. Brooijmans, N.; Kuntz, I. D. Molecular recognition and docking algorithms. Annu. Rev. Biophys. Biomol. Struct. 2003, 32, 335-373.
68. (a) Bender, A.; Glen, R. C. A discussion of measures of enrichment in virtual screening: comparing the information content of descriptors with increasing levels of sophistication. J. Chem. Inf. Model. 2005, 45, 1369-1375.
69. (b) Bender, A.; Mussa, H. Y.; Reiling, S.; Glen, R. C. Similarity searching of chemical databases using atom environment descriptors (MOLPRINT 2D): evaluation of performance. J. Chem. Inf. Model. 2004, 44, 1708-1718.
70. (c) Glen, R. C.; Bender, A.; Arnby, C. H.; Carlsson, L.; Boyer, S. and; Smith, J. Circular fingerprints: flexible molecular descriptors with applications from physical chemistry to ADME. IDrugs 2006, 49, 199-204.
71. For a Review of the application of microwave chemistry to medicinal chemistry,
72. see: (a) Alcazar, J.; Diels, G.; Schoentjes, B. Microwave assisted medicinal chemistry. Mini-Rev. Med. Chem. 2007, 7, 345- 369.
73. (b) Alcazar, J.; Diels, G.; Schoentjes, B. Applications of the combination of microwave and parallel synthesis in medicinal chemistry. Comb. Chem. High Throughput Screen. 2007, 10, 918- 932.
74. [3H]Astemizole binding assays in HEK293 cells expressing HERG K+ channels were performed following the procedure disclosed in the literature: Chiu, P. J. S.; Marcoe, K. F.; Bounds, S. E.; Lin, C.-H.; Feng, J.-J.; Lin, A.; Cheng, F.-C.; Crumb, W. J.; Mitchell, R. Validation of a [3H]astemzole binding assay in HEK293 cells expressing HERG K+ channels J. Pharmacol. Sci. 2004, 95, 311-319.
75. Andres-Gil, J. I.; Alcazar-Vaca, M. J.; Alvarez-Escobar, R. M.; Oyarzabal-Santamarina, J.; Dautzenberg, F. M.; Macritchie, J.; Simpson, D. and Martinez Gonzalez, S.Preparation of aryl and heteroaryl substituted pyrazinone derivatives for use in melaninconcentrating hormone mediated diseases. Patent WO07071646 A1; 139 pp.
76. Bastian, J. L.; Chirgadze, N. Y.; Denney, M. L.; Foglesong, R. J.; Harper, R. W.; Johnson, M. G.; Klimkowsky, V. J.; Kohn, T. J.; Lin, H.-S.; Lynch, M. P.; Mccowan, J. R.; Palkowitz, A. D.; Richett, M. E.; Sall, D. J.; Smith, G. F.; Takeuchi, K.; Tinseley, J. M. and Zhang, M.Preparation of [(pyrrolidinoalcoxy)phenyl+benzothiphenes and analogues as thrombin inhibitors. Patent WO9725033 A1; 43 pp.